Genetically engineered NSCs possess inherent tumor-tropic properties that allows them to migrate toward and deliver therapeutic gene products such as proapoptotic agent tumor necrosis factor-α (TNF-α)-related apoptosis-inducing ligand (TRAIL) to local or distant GBM foci. This evidence concerns the gene TNFSF10 and neoplasm.